IP Library Granted Patent US 10,618,964
Granted Patent B2
US 10,618,964 · App. 13/263,223 · Granted Apr 14, 2020

Nanobody against IL-6R

Inventors: Veerle Compernolle (Veldegem, BE); Francis Descamps (Roeselare, BE)
Assignee: Ablynx N.V.
C07K16/2866C07K2317/22C07K2317/24C07K2317/569C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,618,964
App. No.
13/263,223
Granted
Apr 14, 2020
Kind
B2
Abstract

The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, methods for preparing such amino acid sequences and polypeptides, host cells expressing or capable of expressing such amino acid sequences or polypeptides, compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Claims (7)

1. An isolated Nanobody that binds to IL-6R and consists essentially of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

CDR1 consists essentially of the amino acid sequence of SEQ ID NO: 350;

CDR2 consists essentially of the amino acid sequence of SEQ ID NO: 520; and

CDR3 consists essentially of the amino acid sequence of SEQ ID NO: 690.

2. The Nanobody according to claim 1 , that consists essentially of the amino acid sequence of SEQ ID NO: 180.

3. A composition comprising the Nanobody of claim 1 .

4. The composition according to claim 3 , which is a pharmaceutical composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2012
From: COMPERNOLLE, VEERLE; DESCAMPS, FRANCIS
To: ABLYNX N.V.
Reel/Frame 027954/0071 →
Continuity (2)
Provisional Application 61168379 · Apr 10, 2009
Related Publication 20120171209A1 · Jul 5, 2012
Cited By (1)
US 12,291,573